View Financial HealthBiotron 배당 및 자사주 매입배당 기준 점검 0/6Biotron 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-36.0%자사주 매입 수익률총 주주 수익률-36.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). MD & Executive Director Michelle Miller is the most experienced director on the board, commencing their role in 2002. Independent & Non-Executive Chairman Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.Board Change • May 01Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent & Non-Executive Director Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공시 • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.공시 • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights OfferingBoard Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michael Medway was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing공시 • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.공시 • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offering공시 • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$9.02m market cap, or US$5.67m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m).Board Change • Feb 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Dec 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공시 • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.공시 • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney AustraliaNew Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$20.8m market cap, or US$14.0m).New Risk • Sep 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.63m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m).New Risk • Jun 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.7m free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$33.4m market cap, or US$22.2m).공시 • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.New Risk • Jul 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (AU$3.0m revenue, or US$2.1m). Market cap is less than US$100m (AU$31.6m market cap, or US$21.7m).Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 BIT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: BIT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Biotron 배당 수익률 vs 시장BIT의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (BIT)n/a시장 하위 25% (AU)2.8%시장 상위 25% (AU)6.9%업계 평균 (Biotechs)2.2%분석가 예측 (BIT) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 BIT 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 BIT 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 BIT 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: BIT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YAU 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 14:27종가2026/05/20 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Biotron Limited는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. 2 independent directors (5 non-independent directors). MD & Executive Director Michelle Miller is the most experienced director on the board, commencing their role in 2002. Independent & Non-Executive Chairman Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.
Board Change • May 01Less than half of directors are independentThere are 6 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 3 independent directors. 5 non-independent directors. Independent & Non-Executive Director Paul Kasian was the last independent director to join the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공시 • Mar 30Biotron Limited Appoints Graeme Wald as Non-Executive Director, Effective March 30, 2026Biotron Limited announced the appointment of Graeme Wald as Non-Executive Director, effective March 30, 2026. Graeme is an Industrial Chemist and has worked as a research chemist in South Africa, Israel and the USA. He became an equities analyst and while at Merril Lynch was rated the top analyst in the Pharmaceuticals and Healthcare sector in South Africa and was a member of the top-rated Global Paper & Pulp research team. In Australia he played a leading role in growing Wilson HTM’s Life Science business to the largest in the country while Head of Lifescience research. He has extensive experience in private equity and venture capital as an Investment Director at BioScience Managers, and a Partner in Fund III at OneVentures. He has played a major role in raising more than $750M for companies in the sector and was Chairman of the Risk & Audit Committee of Nexvet Inc. while a director of the company through to its NASDAQ listing. He was also founding Chairman of Prota Therapeutics Pty Ltd. and acting CEO. He is also CEO and Director of MyrioTherapeutics Pty Ltd, a Melbourne based antibody drug company developing novel antibodies for the treatment of solid tumours and is Chairman of Psaio Therapeutics, also Melbourne based that is developing novel antibodies for the treatment of prostate cancer based on Myrio technology. He is Chairman of US based Hula Therapeutics, a private company in the clinical stage of developing a treatment for paediatric neuroblastoma, using technology partly developed by Myrio.
공시 • Jan 30Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1.52386 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 215,286,751 Price\Range: AUD 0.003 Discount Per Security: AUD 0.00018 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 292,666,664 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Rights Offering
Board Change • Dec 24Less than half of directors are independentFollowing the recent departure of a director, there are only 3 independent directors on the board. The company's board is composed of: 3 independent directors. 4 non-independent directors. Independent Non-Executive Director Michael Medway was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Dec 02Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,664 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,669 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Oct 15Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 199,086,876 Price\Range: AUD 0.003 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 134,246,457 Price\Range: AUD 0.003 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
공시 • Sep 29Biotron Limited, Annual General Meeting, Nov 17, 2025Biotron Limited, Annual General Meeting, Nov 17, 2025.
공시 • Feb 28+ 1 more updateBiotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 652,382,667 Price\Range: AUD 0.003 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 250,000,000 Price\Range: AUD 0.003 Transaction Features: Rights Offering
공시 • Feb 21Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million.Biotron Limited has filed a Follow-on Equity Offering in the amount of AUD 2.707148 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 270,714,829 Price\Range: AUD 0.01
New Risk • Feb 12New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$9.02m market cap, or US$5.67m). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.0m).
Board Change • Feb 04Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Dec 24Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent & Non-Executive Director Rob Thomas was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공시 • Nov 28Biotron Limited Announces Board RetirementDr. Susan Pond and Professor Stephen Locarnini, Non-Executive Directors, have retired as Directors of Biotron Limited (Biotron) as of 28 November 2024. Dr. Pond has been a Director since 7 March 2012 and Professor Locarnini since 23 October 2018.
공시 • Oct 22Biotron Limited, Annual General Meeting, Nov 28, 2024Biotron Limited, Annual General Meeting, Nov 28, 2024. Location: level 38 tower 3 international tower, sydney 300, barangaroo ave sydney, nsw 2000, sydney Australia
New Risk • Sep 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Minor Risks Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$20.8m market cap, or US$14.0m).
New Risk • Sep 10New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: AU$14.4m (US$9.63m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$3.6m free cash flow). Negative equity (-AU$244k). Earnings have declined by 2.6% per year over the past 5 years. Market cap is less than US$10m (AU$14.4m market cap, or US$9.63m). Minor Risks Share price has been volatile over the past 3 months (16% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m).
New Risk • Jun 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-AU$5.7m free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (AU$1.6m revenue, or US$1.1m). Market cap is less than US$100m (AU$33.4m market cap, or US$22.2m).
공시 • Oct 20Biotron Limited, Annual General Meeting, Nov 22, 2023Biotron Limited, Annual General Meeting, Nov 22, 2023, at 11:00 AUS Eastern Standard Time. Location: Level 3, 60 Carrington Street, Sydney, NSW, 2000 Sydney Australia Agenda: To receive and consider the Company's annual financial report, the directors' report and the auditors' report for the year ended 30 June 2023; to consider the That Dr. Susan M. Pond be and is hereby re-elected as a Director; to consider the That the Remuneration Report for the year ended 30 June 2023 be and is hereby adopted; to consider the Re-election of Dr. Susan M. Pond as a Director; and to consider other matters.
New Risk • Jul 14New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 14% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 11% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (14% average weekly change). Shareholders have been diluted in the past year (28% increase in shares outstanding). Revenue is less than US$5m (AU$3.0m revenue, or US$2.1m). Market cap is less than US$100m (AU$31.6m market cap, or US$21.7m).
Board Change • Nov 17Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 4 highly experienced directors. Independent & Non-Executive Director Stephen Locarnini was the last director to join the board, commencing their role in 2018. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.